



## Prior Authorization Approval Criteria

### *Emend (aprepitant)*

<b>Generic name:</b>	Aprepitant
<b>Brand name:</b>	Emend
<b>Medication class:</b>	Antiemetic; NK1 receptor antagonist
<b>FDA-approved uses:</b>	In combination with other antiemetics agents, aprepitant is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic agents.  Prevention of postoperative nausea and vomiting.
<b>Usual dose range:</b>	<i>Prevention of chemotherapy-induced nausea and vomiting:</i> Day 1: aprepitant 125 mg PO, dexamethasone 12 mg PO and odansetron 32 mg IV  Day 2-3: aprepitant 80 mg PO QD and dexamethasone 8 mg PO QD  <i>Prevention of postoperative nausea and vomiting:</i> 40 mg within 3 hours prior to induction of anesthesia.
<b>Duration of therapy:</b>	<i>Prevention of chemotherapy-induced nausea and vomiting:</i> 3 days per cycle <i>Prevention of postoperative nausea and vomiting:</i> day of surgery

**Criteria for use** (*bullet points below are all inclusive unless otherwise noted*):

- Undergoing surgery and requires prevention of postoperative nausea and vomiting.
- OR
- Use of highly emetogenic chemotherapy agent
  - Concurrent use of dexamethasone (needed for regimen)
  - Failed or intolerant to 5HT3's :Zofran, Kytril, Anzemet.

**Not approved if:**

- Used as continuous therapy (manufacturer does not recommend use in this way due to drug-interaction profile)
- OR
- 5HT3 is to be used concurrently (Zofran, Kytril, Anzemet)
- OR
- Dexamethasone cannot be used.

**Caution:**

- Metabolized by CYP3A4. Chemotherapeutic meds that are metabolized by CYP3A4 whose concentrations could increase: docetaxel, ifofosfamide, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, vincristine.
- Warfarin: INR may decrease; monitor 7-10 days after Emend use

FCHP Pharmacy and Therapeutics Committee approval: \_\_\_\_\_

Date: \_\_\_\_\_

Adopted: 11/16/04  
First revision: 12/12/07